Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for bone marrow protection in gynecologic cancer patients receiving pelvic radiotherapy
ChiCTR2600126807Phase 4Not yet recruiting
- Sponsor
- Shandong First Medical University
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of romiplostim in Cervical Cancer (CC), endometrial cancer (EC), ovarian cancer and 2 more (2 arms), sponsored by Shandong First Medical University. Primary endpoint: Incidence of Grade 3 or Higher Thrombocytopenia. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)ovarian cancerVulval carcinomavaginal cancer
Beyond the preview
Go deeper on ChiCTR2600126807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126807.